| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 |
Form 4: Parshall B Lynne, Director
Sold 5,000 shares ($274K) |
| 10 Nov 2026 | SCHEDULE 13G |
| 09 Nov 2026 | 144 |
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026 and Type II Variation in the European Union in Early 2027 |
| 03 Nov 2026 |
Form 4: Malik Fady Ibraham, EVP Research & Development
Received 3,500 shares by exercise or conversion ($27.3K) · Sold 3,500 shares ($220K) |
| 02 Nov 2026 |
Form 4: Blum Robert I, Director
Received 7,500 shares by exercise or conversion ($79.5K) · Sold 7,500 shares ($471K) |
| 20 Oct 2026 |
Form 4: Wysenski Nancy, Director
Received 97 shares as a grant or award ($6.2K) |
| 20 Oct 2026 |
Form 4: Kaye Edward M. Md, Director
Received 195 shares as a grant or award ($12.5K) |
| 20 Oct 2026 |
Form 4: Harrington Robert Arthur, Director
Received 195 shares as a grant or award ($12.5K) |
| 20 Oct 2026 |
Form 4: Daly James M, Director
Received 195 shares as a grant or award ($12.5K) |
| 20 Oct 2026 |
Form 4: Wierenga Wendell, Director
Received 97 shares as a grant or award ($6.2K) |
| 20 Oct 2026 |
Form 4: Henderson John T, Director
Received 352 shares as a grant or award ($22.5K) |
| 20 Oct 2026 | 144 |
| 20 Oct 2026 |
Form 4: Malik Fady Ibraham, EVP Research & Development
Received 3,500 shares by exercise or conversion ($27.3K) · Sold 3,500 shares ($224K) |
| 13 Oct 2026 |
Form 4: Blum Robert I, Director
Received 7,500 shares by exercise or conversion ($79.5K) · Sold 7,500 shares ($472K) |
| 13 Oct 2026 | 144 |
| 06 Oct 2026 |
Form 4: Malik Fady Ibraham, EVP Research & Development
Received 3,500 shares by exercise or conversion ($27.3K) · Sold 3,500 shares ($215K) |
| 28 Sep 2026 |
Form 4: Blum Robert I, Director
Received 7,500 shares by exercise or conversion ($79.5K) · Sold 7,500 shares ($491K) |
Loading...